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The therapeutic agents that target ATP-sensitive potassium 
channels
ATP-sensitive potassium (KATP) channels are a major drug 
target for the treatment of type-2 diabetes. KATP channels are 
ubiquitously expressed and link the metabolic state to electri-
cal excitability. In pancreatic β-cells, KATP channels are crucial 
in the regulation of glucose-induced insulin secretion. Also, 
KATP channels are involved in the protection against neuronal 
seizures and ischaemic stress in the heart, brain and in the 
regulation of vascular smooth muscle tone. Functional KATP 
channels are hetero-octamers composed of two subunits, a 
pore forming Kir6, which is a member of the inwardly recti-
fying potassium channels family, and a regulatory sulpho-
nylurea receptor (SUR). In response to nucleotides and phar-
maceutical agonists and antagonists, SUR allosterically 
regulates channel gating. The allosteric communication path-
ways between these two heterologus proteins in KATP chan-
nels are still poorly understood. This review will highlight 
the therapeutic agents that target KATP channels and are used 
to treat diabetes and cardiovascular diseases.
Keywords: ATP-sensitive potassium channels, therapeutic 
agents, diabetes, cardiovascular, inwardly rectifying potas-
sium channels, sulphonylurea receptor
Potassium channels play a significant role in shaping the excitability and firing pat-
terns of cells (1). Potassium channels are divided into four major classes based on their 
structure: two, four, six and seven transmembrane-domain channels (2). There is large 
diversity within potassium channels, including calcium activated, voltage-gated, twin 
pore domain, and inwardly rectifying channel subtypes. Despite this large diversity, the 
members of the channel family have similarities, such as all of them having pore-lining 
P-loops with a consensus amino acid sequence (3).
A biophysical property of inwardly rectifying potassium (Kir) channels is that they 
conduct inward current more readily than outward current (4, 5). Kir channels are crucial 
for stabilizing the resting membrane potential and regulating excitability in many tissues 
(1, 4). This group consists of seven sub-families: Kir1 to Kir7. All members of the Kir channel 
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family have the same basic structure, which consists of intracellular amino (N) and car-
boxyl (C) termini and two putative membrane spanning segments (M1 and M2) flanking 
a pore-forming P-loop and signature sequence (6–8). 
THE ATP-SENSITIVE POTASSIUM CHANNELS
The Kir channel proteins that have been identified comprise between 360 to 500 ami-
no acids in length. All Kir members are regulated by the membrane phospholipid, phos-
phatidylinositol 4,5-bisphosphate (PIP2), and some are also modulated by other regulatory 
factors or ligands, such as ATP and G-proteins, bearing their common names, ATP-sensi-
tive (KATP) and the G-protein-gated potassium channel (GRK) (8).
ATP-sensitive potassium (KATP) channels, which are unique among potassium chan-
nels, were first described by Akinori Noma in 1983 (9). KATP channels have been identified 
in other tissues, including pancreatic β-cells (10), skeletal muscle cells (11), neuronal cells 
(12) and smooth muscle cells (13). 
The classification of KATP channels is mainly based on pharmacological criteria using 
the potassium channel openers (KCOs, agonists) or sulphonylureas (antagonists). KATP chan-
nels are identified by subunit combinations of sulphonylurea receptor (SUR), SUR1, SUR2A 
and SUR2B, and inward rectifier (Kir), Kir6.1, Kir6.2, in different tissue types (14, 15).
THE PORE-FORMING INWARD RECTIFIER POTASSIUM CHANNEL ISOFORMS 6 (KIR 6)
The Kir6 subfamily is a member of the Kir channel family (16) and comprises the pore 
forming component of the KATP channel (17). There are two Kir6 isoforms, Kir6.1 and 
Kir6.2 (18). Kir6.1 and Kir6.2 isoforms are highly homologous and share 71 % amino acid 
identity with each other (19). These two isoforms form functional KATP channels with 
sulphonylurea receptors (19).
SULPHONYLUREA RECEPTOR
Sulphonylurea receptor (SUR) polypeptides are members of the ATP-binding cassette 
protein of the ABCC/MRP family. Human ABC protein genes are classified into seven 
subfamilies: ABCA to ABCG according to their gene structure, sequence homology and 
phylogenetic relations (20). There are two genes encoding three isoforms of SUR: SUR1, 
which is encoded by the ABCC8 gene, and SUR2 encoded by the ABCC9 gene. The latter 
can be transcribed into two different isoforms, SUR2A and SUR2B (21). These two SUR2 
variants differ solely in the carboxyl-terminal due to alternative 3 -́exon usage (22). In gen-
eral, all ABC proteins contain a minimum of four structural domains: two transmembrane 
domains (TMDs) containing 6 to 8 transmembrane helices each and two cytosolic nucle-
otide binding domains (NBDs), which are involved in nucleotide binding and hydrolysis 
(23). SUR subunits consist of 17 transmembrane polypeptide segments clustered into three 
transmembrane domains (TMD), named TMD0, TMD1 and TMD2. TMD0 consists of the 
first five transmembrane segments and TMD1 and TMD2 consist of six segments each. 
There are two cytoplasmic nucleotide binding domains in each subunit. The first nucleo-
tide binding domain NBD1 is located between transmembrane segments 11 and 12 and the 
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second, NBD2, is located beyond the last transmembrane segment number 17 and forms 
part of the C-terminal domain (21, 24). Both the sequence and the structure of NBDs are 
highly conserved across all prokaryotic and eukaryotic ABC proteins. Each contains a 
conserved Walker A (WA) motif and a Walker B (WB). These motifs catalyse ATP hydrolysis 
and are important for nucleotide regulation of the ABC proteins’ functional activity (25).
As evidenced largely by Clement et al. (26), a functional KATP channel is an octameric 
complex composed of four SUR subunits and four Kir6 subunit, i.e., a 4:4 stoichiometry 
(Kir64/SUR4 ) (27). Binding of SUR to Kir subunits serves two purposes; first, to allow the 
translocation of the channel to the plasma membrane and, second, to contribute to the 
regulation of the channel by interaction between two subunits (28).
THE ROLE OF ATP-SENSITIVE POTASSIUM CHANNELS IN DIFFERENT TISSUES 
AND CELL TYPES
KATP channels couple cell metabolism to electrical activity in nerve, muscle and endo-
crine cells and play an important role in various cellular functions as sensors of intracel-
lular ATP and ADP coupled to electrical function (18). KATP channels have important roles 
in many tissues under both physiological and pathological conditions (29).
The KATP channel has a key role in the physiology of many cells and defects in the 
channel itself or in its regulation such as in hyper/hypo-glycemia, ischaemia, hormone 
secretion and excitability of muscles/neurons causes human diseases (30). 
KATP channels are crucial in the regulation of glucose-induced insulin secretion (18). 
In pancreatic β-cells, an increase in ATP/ADP ratio, generated by glucose uptake and meta-
bolism, closes the KATP channels to elicit membrane depolarisation, calcium influx (open-
ing of voltage-gated Ca2+ channels) and secretion of insulin, the primary hormone of glu-
Fig. 1. Subunit structure of the ATP-sensitive potassium channel.
Schematic drawing showing the topology of the SUR and Kir6 subunits in KATP channels. The SUR 
subunit comprises the three transmembrane domains TMD0, TMD1 and TMD2, the two nucleotide 
binding domains NBD1 and NBD2, the extracellular N- and the intracellular C-termini and the pore-
forming Kir subunit. Each Kir subunit consists of two transmembrane helices M1 and M2 and a 
pore-forming region containing the pore-helix, and intracellular N- and C-termini.
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cose homeostasis. In hyperglycaemia, increased transport of glucose into the β-cells occurs 
resulting in an elevated intracellular ATP, promoting closure of the KATP channels and 
membrane depolarization (31). This KATP channel mechanism can be mimicked by sulpho-
nylurea drugs, for example, glibenclamide, which inhibits the KATP channel directly in 
pancreatic β-cells (32).
Potassium channels are critical to cardiac excitability because they play fundamental 
roles in setting the resting membrane potential, RMP, and in repolarisation of the action 
potential (AP). Under normal conditions, the cardiac sarcolemmal KATP channel is pre-
dominately closed (33). The channel activates during various forms of metabolic stress, 
including ischaemia, hypoxia, hyperglycemia, hypoglycaemia and inhibition of glycolysis 
and/or oxidative phosphorylation (34, 35). 
In the vascular smooth muscle cells, KATP channels are thought to play important roles 
such as mediating the response of the vascular smooth muscle to a variety of pharmaco-
logical and endogenous vasodilators and also to changes in metabolic activity that can 
directly influence blood flow in various tissues (36). Most of the KATP channels in vascular 
muscle cells are rather insensitive to ATP and they are activated by nucleoside diphos-
phates and inhibited by glibenclamide (37).
KATP channels have been identified in various other tissues, including neurons, brain 
and skeletal muscle (30). KATP channels have been shown to be expressed in several regions 
of the brain, including the substantia nigra (38, 39) and in the hypothalamus (40). Evidence 
has shown that the KATP channels are also expressed in the substantia nigra area of the brain 
(41). It has been proposed that KATP channels play a role in the suppression of seizures in 
ATP-depleted conditions (42).
In the skeletal muscles, KATP channels have been identified by electrophysiological 
methods (43). The channels are mainly located in the plasma membrane, appear in all fibre 
types and are active in the resting human muscle. KATP channels located in the sarcolem-
ma contribute significantly to membrane permeability in the resting human muscle and 
are important for the interstitial K+ balance (44). 
THE PHARMACOLOGY OF ATP-SENSITIVE POTASIUM CHANNELS
KATP channels are the major drug target and have the most therapeutic potential 
among potassium channels (3, 12, 45). Pharmacological treatment of a number of clinical 
conditions, such as angina and Type 2 diabetes, are targeted on the KATP channel, though 
in different ways. To treat angina, agonists such as potassium channel openers (KCOs), e.g., 
nicorandil, are used to open the KATP channels in vascular smooth and cardiac muscles. In 
contrast to KCOs, antagonists such as sulphonylureas and related drugs are used to close 
KATP channels in pancreatic β-cells with, for example, tolbutamide or glibenclamide. Both 
types, agonists and antagonists, target the various SUR subunits to either open or close the 
channels. 
It has been shown that co-expression of Kir6.2/SUR2A, Kir6.2/SUR2B, and Kir6.1/
SUR2B reconstitutes the cardiac, smooth muscle and vascular smooth muscle KATP chan-
nels, respectively (46, 47). These channels have different sensitivities to ATP. They also 
show different responses to sulphonylurea drugs and potassium channel openers (19, 48, 
49) permitting tissue selectivity in KATP channel directed therapies. 
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Table I. Classification of sulphonylureas, the ATP-sensitive potassium channel antagonists
Pharmacologic class Mechanism of action Clinical use
Sulphonylurea
First 
generation e.g., tolbutamide 
blocking KATP channels in 
pancreatic β-cells prevents K+ 
efflux and causes 
depolarization of the plasma 
membrane, then opens Ca2+ 
channels, causing influx of 
Ca2+ and insulin release
type 2 diabetes 
mellitus
Second 
generation e.g., glibenclamide 
Third 
generation e.g., glimepiride 
SULPHONYLUREAS
Sulphonylurea compounds were originally intended to be antimicrobial agents dur-
ing World War II. At that time, it was observed that a common side effect was hypoglycae-
mia, now known to be due to the inhibition of pancreatic β-cell KATP channels. Today, 
sulphonylureas are used to treat type 2 diabetes (Table I) (50–52).
The target of sulphonylurea is the plasma membrane expressed KATP channel. At this 
site, sulphonylurea causes channel closure, which results in depolarization of the β-cell 
membrane and stimulation of insulin secretion (53). Kir6.2/SUR1 KATP channels are inhibi-
ted by glibenclamide (absolute inhibition constant Ki ~10 nmol L–1). Kir6.2/SUR2A, Kir6.2/
SUR2B and Kir6.1/SUR2B KATP channels are inhibited with Ki values in the low micromo-
lar range (16, 19, 48). The binding is isoform dependent; the β-cell isoform SUR1 binds only 
tolbutamide and gliclazide and SUR2A and SUR2B bind all other types of sulphonylureas 
(51, 54–57).
As mentioned earlier, KATP channels are expressed ubiquitously however, sulphony-
lureas can cause undesired side effects since these drugs can cross-react with different 
KATP channel subtypes (58, 59). Chlorpropamide, acetohexamide, tolazamide and tolbuta-
mide are the first-generation sulphonylureas and the action of these drugs is long lasting 
with considerable excretion in the urine (60). Hence, these drugs should be prescribed with 
cation for elderly patients with impaired kidney function (61).
Glyburide, glipizide and gliclazide are the second-generation sulphonylureas and 
they differ in pharmacokinetics and duration of action. It is worth mentioning that the 
second-generation sulfonylureas are more potent than the first-generation (60). A retro-
spective cohort study identified significant differences in ones risk of severe hypoglycae-
mia among users of individual sulphonylureas among older people (61). This study found 
relatively high incidence of hypoglycaemia in patients taking glyburide or chlorpropa-
mide. Moreover, this study suggested a shorter-duration sulphonylureas such as glipizide 
elderly patients who cannot tolerate metformin as initial monotherapy (61).   
Despite the differences in absorption and metabolism between the first- and second-
generation sulphonylureas, they are equally effective in lowering blood glucose concentra-
tions (62). Moreover, due to their structural characteristics, much lower doses of second-
generation sulfonylureas are given than of the first generation (62).  It has been reported 
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that in patients with type 2 diabetes, glimepiride caused low incidence of severe hypogly-
caemia compared to glibenclamide (63). Also, the duration of glimepiride action is up to 24 
hours (64).
Hirst et al. (65) reported that sulphonylurea monotherapy reduced HbA1c by an aver-
age of 1.5 % compared to that of placebo groups in a systematic review of double-blind 
randomized control trials. Sulphonylureas can lower the fasting blood glucose concentra-
tions as extrapancreatic effects of these drugs. In other words, these drugs suppress the 
overnight hepatic glucose output (61, 66).
POTASSIUM CHANNEL OPENERS
Potassium channel openers are a chemically diverse group of agents, exemplified by 
pinacidil, levcromakalin, aprikalim, and nicorandil (Table II) (3, 12, 14, 25, 51, 67). These 
KCOs activate KATP channels (67–69). These agents possess high therapeutic potential in 
treating various clinical conditions such as hypertension, acute and chronic myocardial 
ischaemia, or congestive heart failure, and also in managing bronchial asthma, urinary 
incontinence and certain skeletal muscle myopathies (3, 45, 69). The effect of opening the 
KATP channel with KCOs is causing a shift of the membrane potential towards the reversal 
potential for potassium and, thereby, reducing it to the cellular electrical excitability. 
The KATP channel subtype, which is stimulated by diazoxide, is Kir6.2/SUR1. How-
ever, these channels are not stimulated by pinacidil or cromakalim (48, 54). In contrast, 
Kir6.2/SUR2A KATP channels are not stimulated by diazoxide but are stimulated by pina-
cidil and cromakalim (16, 19). Similarly, Kir6.2/SUR2B KATP channels are stimulated by 
both pinacidil and cromakalim (16, 70). Since nucleotide binding and/or hydrolysis at both 
NBDs of SUR subunits are taken to be crucial for the specific binding and action of these 
potassium channel openers (19, 54, 70, 71) and for slowing down the off-rate of pinacidil 
(72), it is believed that the differences in sulphonylurea sensitivity between these channel 
subtypes may be caused partially by differences in nucleotide sensitivity of the different 
SUR isoforms (19). 
Table II. The potassium channel openers that target the ATP-sensitive potassium channels










Opening of KATP 
channels causing K+ 
efflux, hyperpolarization 
of the cell membrane 
and smooth muscle 
relaxation leading to 
vasodilation and drop in 
blood pressure
Minoxidil hair growth stimulant, severe hypertension 
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The clinical use of potassium channel opening drugs has been limited due to the dif-
ficulties in developing tissue- and condition-selective K+ channel-opening drugs (70). Dif-
ferent KCOs bind to different transmembrane polypeptide segments of the SUR. Within 
the 17 transmembrane polypeptide segments, the binding of pinacidil and cromakalim 
occurs at two domains within the helices numbered 16 and 17 (73), and in the cytoplasmic 
loop between segments 13 and 14 (74, 75). The binding site for diazoxide is not so well 
characterized. It is believed that diazoxide binding is nucleotide dependent (73). In SUR1, 
diazoxide binding has been mapped to bind between helices 8 to 11 and in the C-terminal 
region incorporating helix 17 and NBD2 (73). 
One of KCOs functions is to activate sarcKATP on vascular smooth muscle cells and 
cardiac myocytes, which leads to potassium ion efflux and membrane hyperpolarization. 
This in turn will reduce calcium influx and reduce the duration of the action potential, 
resulting in a negative inotropic effect in cardiomyocytes and vasodilatation of blood ves-
sels (76, 77). First-generation drugs, including cromakalim and pinacidil, were aimed at 
treating hypertension; however, such medications failed to achieve clear benefits over 
angiotensin-converting enzyme inhibitors or calcium antagonists (78).
Selective KCO bimakalin did not show any anti-ischemic benefits in patients suffering 
from coronary artery disease during exercise-induced angina pectoris. However, the drug 
did cause a dose dependent vasodilatory activity (79). Studies, including one by Ueda et al. 
(80), have shown that KCO nicorandil administered intravenously can reduce the occur-
rence of ventricular fibrillation and QT dispersion in patients with acute myocardial inf-
arction (AMI) undergoing successful coronary angioplasty. According to the Ueda study, 
this would prevent the occurrence of cardiac events following successful percutaneous 
transluminal coronary angioplasty for AMI patients. The administration of nicorandil to 
patients with stable angina in an angina (IONA) study (81) effectively reduced the rates of 
the combined primary endpoint of coronary heart disease mortality, myocardial infarc-
tion, or admission for chest pain, and the secondary endpoint of coronary heart disease 
mortality, myocardial infarction, or unstable angina and the rates of cardiovascular events.
Another KATP channel opener, levosimendan, which is a calcium sensitizer and inodi-
lator, has been shown to significantly reduce pulmonary capillary wedge pressure in pa-
tients with severe low-output heart failure following cardiac surgery as well as in a case 
of peripartum cardiomyopathy (82). In controlled trials, levosimendan has been shown to 
decrease mortality rates in patients with severe low-output heart failure and in patients 
with left ventricular failure after AMI (83, 84). 
CONCLUSIONS
In response to nucleotides and pharmaceutical agonists and antagonists, SUR allos-
terically regulate the KATP channel gating in a functional KATP channel complex Kir64/
SUR4. However, the transduction pathways for allosteric communication, which make the 
functional link between the pore forming Kir6 and the regulatory SUR subunits of KATP 
channels remain poorly understood. 
To design novel and more effective drugs for the treatment of diabetes, high blood 
pressure and/or use as a cardioprotective agent in heart attack or cardiac surgery (thera-
peutic importance), the three-dimensional crystal structure of the functional KATP channel 
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needs to be determined. The crystal structure will clarify the allosteric communications 
between KATP channel subunits that induce the conformational changes and channel gat-
ing.
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